Apr 5, 2022 | Press Releases
HDT Bio’s technology uses self-replicating RNA and has the potential to deliver a COVID-19 vaccine targeting multiple variants, providing broad protection from disease and reduced transmission from breakthrough infections Seattle, WA, (April 5, 2022) – HDT Bio Corp.,...
Mar 29, 2022 | Press Releases
HDT’s technology offers simpler manufacturing, easier deployment, and requires much lower doses than existing COVID-19 RNA vaccines, enabling global supply. Vaccine targets Beta variant; has demonstrated effectiveness against other variants; will be evaluated as...
Jan 17, 2022 | Press Releases
HDT Bio’s RNA-based vaccine offers simpler manufacturing, easier deployment without the need for ultra-low freezers, and requires vastly lower dosing than current RNA COVID-19 vaccines SEATTLE & SALVADOR, Brazil–January 17, 2022–HDT Bio Corp., a U.S....
Dec 13, 2021 | Press Releases
HDT’s RNA-based vaccine offers simpler manufacturing, greater stability, and vastly lower effective dosing than current mRNA COVID-19 vaccines Quratis could make vaccine available across East Asia Seattle, WA, and Seoul, KOREA (December 13, 2021) – HDT Bio Corp., a...
Aug 31, 2021 | Press Releases
Agreement extends HDT Bio’s international COVID 19 vaccine partnerships as part of its long-term goal of changing the global-health paradigm to address global-health inequity The company’s RNA-based vaccine offers simpler manufacturing, easier deployment without the...
